🔬 Advancing the Fight Against Lung Cancer
Support a Groundbreaking Clinical Trial of ImmunoFolate (ImmunoPterin)
🔬 Advancing the Fight Against Lung Cancer
Support a Groundbreaking Clinical Trial of ImmunoFolate (ImmunoPterin)
A Transformative Immunotherapy for NSCLC
ImmunoFolate Therapeutics by SanRx is launching a first-in-human clinical trial for ImmunoPterin (ImmunoFolate)—a novel folate-based immunotherapy designed to reprogram the immune system against non-small cell lung cancer (NSCLC).
We are currently raising $10 million to fund this pivotal clinical program.
🧬 Why ImmunoFolate?
Non-small cell lung cancer remains one of the most lethal forms of cancer worldwide, with limited durable responses to existing immunotherapies. ImmunoFolate offers a first-in-class mechanism that:
- Stimulates antigen-presenting cells (APCs)
- Enhances T-cell activation
- Operates through natural immune morphogenetic pathways
- Has demonstrated potent anti-tumor effects in preclinical models
This immune-modulating approach represents a new frontier in oncology—merging metabolic signaling with precision immunotherapy.
Site Content
🧪 Our Clinical Roadmap
Phase I/II Clinical Trial Objectives:
- Assess safety and tolerability of ImmunoFolate in NSCLC patients
- Establish optimal dosing
- Evaluate immune response and preliminary signs of efficacy
Use of Funds ($10M):
- IND-enabling studies and FDA submission
- GMP manufacturing of clinical-grade ImmunoFolate
- Clinical site selection, patient recruitment, and trial execution
- Biomarker and immunologic response analysis
📈 A Compelling Market Opportunity
- NSCLC accounts for ~85% of all lung cancer diagnoses
- Global NSCLC immunotherapy market projected to exceed $25B by 2030
- Urgent need for immune-based therapies with novel mechanisms of action
🧪 Our Clinical Roadmap
Phase I/II Clinical Trial Objectives:
- Assess safety and tolerability of ImmunoFolate in NSCLC patients
- Establish optimal dosing
- Evaluate immune response and preliminary signs of efficacy
Use of Funds ($10M):
- IND-enabling studies and FDA submission
- GMP manufacturing of clinical-grade ImmunoFolate
- Clinical site select
Welcome
Hello
SanRx is a biopharmaceutical company committed to developing innovative immunotherapy solutions that enhance the immune system's capabilities in combating diseases. Our flagship product, ImmunoFolate, is designed to enhance and modulate immune responses.
SanRx Pitch Deck
🤝 Partner With Us
We are actively seeking strategic investors, venture partners, and clinical collaborators to join us in advancing this high-impact therapy to the clinic.
If you're an investor, biotech executive, or healthcare advocate passionate about transforming cancer treatment, we invite you to connect with us.
📧 Contact: phil.moheno@san-rx.com
🌐 Learn more: https://www.yriscience.com
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.